National Institute for Health and Care Research

View the accessible transcript of this podcastThomas Jaki, Professor in Statistics at Lancaster University talks to Professor Allan Gaw about the AGILE platform trial which specifically looks at novel (new) treatments for COVID19, as opposed to repurposed treatments. Professor Jaki describes how the efficient platform approach enables investigating treatment benefit (efficacy) and dosage in parallel and explains why AGILE is a stellar example of cross-sector collaboration. He also looks to the future: "we're hoping that the learnings from AGILE is going to lead to a much better, much faster, setting up of studies and a much more efficient way to undertake treatment development in the future."This podcast is part of our 'Perspectives from the Pandemic' series looking at the delivery of Complex and Innovative Design (CID) trials in the COVID-19 pandemic. You can access the full series of #ComplexInnovativeDesign trial podcasts on our website: www.nihr.ac.uk/documents/delivering-complex-and-innovative-trials-podcast-collection/29517 To find out more about how the NIHR supports complex and innovative design trials, visit: www.nihr.ac.uk/innovative-trials

View the accessible transcript of this podcast Professor Tim Maughan talks to Professor Allan Gaw about lessons learnt from delivering the world-renowned, molecularly stratified FOCUS4 platform trial  He explains how this flagship trial was designed to respond to a need for a systematic approach to quickly understand which emerging, innovative cancer treatments worked against which cancers. He also describes why one of the biggest challenges was engaging life science companies. Finally he points to how this, and other ground-breaking cancer platform trials, have paved the way for COVID19 platform trials like RECOVERY which have saved thousands of lives around the globe. This podcast is part of our 'Perspectives from the Pandemic' series looking at the delivery of Complex and Innovative Design (CID) trials in the COVID-19 pandemic. You can access the full series of #ComplexInnovativeDesign trial podcasts on our website: www.nihr.ac.uk/documents/delivering-complex-and-innovative-trials-podcast-collection/29517 To find out more about how the NIHR supports complex and innovative design trials visit: www.nihr.ac.uk/innovative-trials

View the accessible transcript of this podcastDr Emma Gray talks to Professor Allan Gaw about the clinical trial platform for Multiple Sclerosis studies, known as 'Octopus'.She explains how the Multi-Arm, Multi-Stage platform trial design will help to speed up the development of novel or repurposed treatments for MS that can slow neurodegeneration and/or protect nerves from further damamge (neuroprotective). She also explains how the research team looked to the STAMPEDE prostate cancer trial for inspiration, and how cross-sector collaboration with the NIHR, the life sciences industry and chariites was crucial.This podcast is part of our 'Persectives from the Pandemic' series looking at the delivery of Complex and Innovative Design (CID) trials in the COVID-19 pandemic. You can access the full series of #ComplexInnovativeDesign trial podcasts on our website: www.nihr.ac.uk/documents/delivering-complex-and-innovative-trials-podcast-collection/29517To find out more about how the NIHR supports complex and innovative design trials, visit: www.nihr.ac.uk/innovative-trials

View the accessible transcript of this podcastDr Hugh Davies talks to Professor Allan Gaw about how research ethics approval services adpated during the pandemic to rapidly approve urgent public health research applications. As well as pointing to practical shifts, such as the switch from fewer face to face meetings to more frequent Zoom meetings, Dr Davies also describes a change of mindset. He describes how ethics panels had to revisit how they assess the benefit and risk balance when considering the burden of delivering research in a pandemic situation, against the desperate need to generate clinical evidence for what treatments work, and don't work.This podcast is part of our 'Persectives from the Pandemic' series looking at the delivery of Complex and Innovative Design (CID) trials in the COVID-19 pandemic. You can access the full series of #ComplexInnovativeDesign trial podcasts on our website: www.nihr.ac.uk/documents/delivering-complex-and-innovative-trials-podcast-collection/29517To find out more about how the NIHR supports complex and innovative design trials, visit:www.nihr.ac.uk/innovative-trials

View the accessible transcript of this podcastProfessor Matt Sydes talks to Professor Allan Gaw about some of the challenges that researchers need to consider when communicating research findings to participants who have taken part in complex design trials such as a MAMS trial - multi-arm, multi-stage trial.If a multi-arm platform trial answers more than one research question, should ALL participants hear about ALL the findings? Or just the arm they participated in? Matt draws on his experiences of the world-renowned STAMPEDE trial to offer some guidance.This podcast is part of our 'Persectives from the Pandemic' series looking at the delivery of Complex and Innovative Design (CID) trials in the COVID-19 pandemic. You can access the full series of #ComplexInnovativeDesign trial podcasts on our website: www.nihr.ac.uk/documents/delivering-complex-and-innovative-trials-podcast-collection/29517To find out more about how the NIHR supports complex and innovative design trials, visit: www.nihr.ac.uk/innovative-trialsYou can listen to all our full collection of #ComplexInnovativeDesign trial podcasts on our website

View the accessible transcript of this podcastProfessor Sir Munir Pirmohamed talks to Professor Allan Gaw about how the UK was able to rapidly adapt to the quest to find new treatments for COVID-19. He points to key ingredients such as the NIHR research workforce, fast-tracked funding decisions, reduced bureaucracy, collaborative research culture - all of which contributed to the UK's success. Importantly, he also recognises that none of this could have been possible without the infrastructure and data systems provided by the NHS and he explains how the UK's integrated health research system was critical to the delivery of the hugely successful COVID-19 platform trials.This podcast is part of our 'Persectives from the Pandemic' series looking at the delivery of Complex and Innovative Design (CID) trials in the COVID-19 pandemic. You can access the full series of #ComplexInnovativeDesign trial podcasts on our website: www.nihr.ac.uk/documents/delivering-complex-and-innovative-trials-podcast-collection/29517To find out more about how the NIHR supports complex and innovative design trials, visit: www.nihr.ac.uk/innovative-trials

View the accessible transcript of this podcastIn this episode we are talking about viral hepatitis. You will hear from Professor Andrew Ustianowski, NIHR's National Specialty Co-Lead for Infection and Professor William Rosenberg, NIHR's National Specialty Lead for Hepatology. They will be taking a look at how the research environment in the UK has enabled rapid developments in the treatment of viral hepatitis with a particular focus on commercial clinical research.You can listen to all our full collection of #ComplexInnovativeDesign trial podcasts on our website.To find out more about how the NIHR supports complex and innovative design trials, visit the NIHR website: www.nihr.ac.uk/innovative-trials  

View the accessible transcript of this podcastIn this episode you will hear from the national trainee leads for Ear, Nose and Throat (ENT); Jameel Muzzaffar, Rishi Mandavia and Matthew Smith - who is also the co-founder of the INTEGRATE UK Trainee Network. They explain how using an innovative and efficient way of working, devised in the UK, they are able to help answer key research questions in ENT with minimal resources. They showcase the SEASHELL study a national multi-center cohort study of patients with sudden onset central hearing loss in the NHS which as recruited over 650 patients at 75 sites with very little funding. They also about how the NIHR and the INTEGRATE network provides opportunities for trainees to gain vaulable experience in delivering and coordinating clinical research and helps to develop the next generation of ENT researchers.You can listen to all our full collection of #ComplexInnovativeDesign trial podcasts on our website.To find out more about how the NIHR supports complex and innovative design trials, visit: www.nihr.ac.uk/innovative-trials

View the accessible transcript of this podcastEmma Lowe talks to Professor Allan Gaw about how the UK was able to get world-renowned, innovative platforms trials - such as RECOVERY, REMAP-CAP and PRINCIPLE - up and running at record speed in order to rapidly deliver answers about which medicines were effective in treating COVID.She reflects on how the uptake and acceptance of forward-thinking trial designs and delivery techniques accelerated during the pandemic as innovation went mainstream. She also zooms in on other stand out features such as the flexibility of the regulators, the ingenious use of data to direct and manange research resources, and the shift in mindset which saw decentralised and virtual trials being delivered in peoples homes.This podcast is part of our 'Persectives from the Pandemic' series looking at the delivery of Complex and Innovative Design (CID) trials in the COVID-19 pandemic. You can access the full series of #ComplexInnovativeDesign trial podcasts on our website: www.nihr.ac.uk/documents/delivering-complex-and-innovative-trials-podcast-collection/29517To find out more about how the NIHR supports complex and innovative design trials, visit: www.nihr.ac.uk/innovative-trialsYou can listen to all our full collection of #ComplexInnovativeDesign trial podcasts on our website.

View the accessible transcript of this podcastProfessor David Sebag Montefiore talks to Professor Allan Gaw about the advantages of the adaptive platform trial design.He zooms in on the PLATO trial (PersonaLising Anal cancer radioTherapy dose) explaining how a traditional approach would have required three separate clinical trial proposals, three separate applications, and three separate trials with three separate teams to manage them. In contrast, the platform approach enabled one research team to answer multiple research questions within one overarching trial platform.To find out more about how the NIHR supports complex and innovative design trials, visit the NIHR website: www.nihr.ac.uk/innovative-trials This podcast is part of our pre-pandemic series of podcasts on Complex and Innovative Design (CID) trials. You can listen to all our full collection of #ComplexInnovativeDesign trial podcasts on our website.